Segabay INC

What Segabay INC does

Segabay Pharmaceutical (黑龙江半岛网页版-半岛(中国)官方制药有限公司) is a privately-held traditional Chinese medicine (TCM) manufacturer based in Jidong County, Heilongjiang Province, China, with an operating history spanning more than 35 years from its 1988 origins as a state-owned enterprise through a 2004 comprehensive restructuring. The company manufactures a portfolio of more than 20 products holding national drug approval numbers (国药准字), anchored by the flagship Yinaoning Tablets (益脑宁片) — a brain-health formulation developed by TCM expert Liang Ruifeng based on Zhang Zhongjing's classical 'Jin Gui Yao Lue' prescription — alongside Ning Shenling Granules (宁神灵颗粒), a Haozhen-branded Acanthopanax extract (好诊刺五加浸膏), Shengtai and Yewujia Acanthopanax tablets, and Pusen Pelvic Inflammation Capsules currently in clinical trials.

The company operates a vertically integrated value chain from upstream GAP-standardized medicinal herb cultivation — including a 10,000 mu Acanthopanax planting base for which it obtained geographic indication authorization in January 2024 — through midstream GMP-certified manufacturing facilities covering tablet, capsule, and granule dosage forms, to downstream nationwide distribution via pharmaceutical wholesalers, third-terminal (tier-3 and below) retailers, and a regional field sales force. It maintains sales and marketing offices in Xi'an High-tech Zone and Beijing, three wholly-owned subsidiaries spanning biotechnology R&D and pharmaceutical manufacturing, and a management team led by General Manager Sun Libao (孙立宝).

Revenue is generated through one-time pharmaceutical product sales; pricing is not publicly disclosed and is handled via a national hotline (400-881-7286). The customer base is composed of diffuse end consumers — patients seeking TCM-based treatments for neurological, mental health, and inflammatory conditions — accessed through fragmented wholesale and retail channels. No revenue figures are publicly disclosed, and the firmographic headcount field (1-10) is materially inconsistent with the documented scale of operations.

Name

Segabay INC

Legal name

黑龙江半岛网页版-半岛(中国)官方制药有限公司

Website

https://segbay.com

Company type

Private

Founded year

1988

Operating status

Operating

Headcount range

1–10 employees

Short description

Segabay Pharmaceutical (黑龙江半岛网页版-半岛(中国)官方) is a privately-held Chinese TCM manufacturer with 35+ years of history, producing 20+ nationally-approved drugs led by Yinaoning Tablets, with vertical integration from a 10,000 mu Acanthopanax GAP base to GMP-certified manufacturing and nationwide wholesale distribution.

Ownership category

akta.pro rank

Product category

Traditional Chinese Medicine Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Traditional Chinese medicine
• Pharmaceutical manufacturing
• Herbal medicine products
• National medicine formulations
• GMP-certified manufacturing

Headquarters

HQ city

Fort Lauderdale

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: The company manufactures and sells traditional Chinese medicine products including Yinaoning Tablets, Ning Shenling Granules, and over 20 national pharmaceutical products (国药准字). Revenue is generated through wholesale and retail pharmaceutical distribution across China, with a nationwide sales network.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Segabay Pharmaceutical manufactures and sells traditional Chinese medicine (TCM) pharmaceutical products with over 20 national-medicine-approved (国药准字) formulations including Yinaoning Tablets (益脑宁片), Ningshenling Granules (宁神灵颗粒), and Acanthopanax-based products such as Haozhen Ci Wu Jia Extract. Products are produced in GMP-certified facilities and distributed through a nationwide pharmaceutical wholesale and retail network targeting third-terminal markets across China.

Product overview

Segabay INC is a traditional Chinese medicine (TCM) pharmaceutical company with over 30 years of history. The company operates a portfolio of 20+ national medicine (国药准字) products, with 益脑宁片 (Yi Nao Ning Pian) as the core product—a brain health formulation developed by expert Liang Ruifeng based on Zhang Zhongjing's classical formula. The company also produces 宁神灵颗粒 and 刺五加浸膏 products under the '好诊' brand, along with other Ci Wu Jia-based products including '野五加刺五加片' and '晟泰刺五加片' under the 'Shengtai' brand. Products span tablets, capsules, and granules, manufactured in GMP-certified facilities. The company is expanding into medicinal herb cultivation with a 10,000 mu Ci Wu Jia planting project and GAP-certified agricultural practices.

Differentiator

Problem solved

Functional benefit

Brands

• 元动力 (Yuandongli): Primary sub-brand for pharmaceutical products including Yinaoning Tablets and related traditional Chinese medicine products
• 好诊 (Haozhen)
• 晟泰 (Shengtai)

Products and services

• Yinaoning Tablets (益脑宁片 / Yi Nao Ning Pian) Core national-medicine-approved (国药准字) brain health tablet formulation developed by TCM expert Liang Ruifeng by re-formulating Zhang Zhongjing's classical "Jin Gui Yao Lue" prescription and integrating modern TCM theory through 30 years of dedicated research. Marketed under the "Yuandongli" (元动力) sub-brand and recognized with county-level intangible cultural heritage designation in October 2024.
• Ningshenling Granules (宁神灵颗粒) National-medicine-approved (国药准字) granular formulation under the "Haozhen" (好诊) brand marketed for mental health management; one of the company's 20+ approved TCM products distributed through the nationwide pharmaceutical wholesale and retail network.
• Haozhen Acanthopanax Extract (好诊 刺五加浸膏 / Hao Zhen Ci Wu Jia Jin Gao) Acanthopanax (Ci Wu Jia) extract product under the "Haozhen" (好诊) brand, manufactured using raw materials from the company's 10,000 mu GAP-certified Acanthopanax planting base. Selected into Heilongjiang Province's third batch of "Nine Treasures Eighteen Products" regional brand certification program in December 2024.
• Ye Wujia Acanthopanax Tablets (野五加刺五加片) Acanthopanax (Ci Wu Jia) tablet formulation selected into Heilongjiang Province's fourth batch of "Nine Treasures Eighteen Products" regional brand certification in October 2025, part of the company's growing Acanthopanax-based product portfolio.
• Shengtai Acanthopanax Tablets (晟泰刺五加片) Acanthopanax (Ci Wu Jia) tablet product under the "Shengtai" (晟泰) brand selected into Heilongjiang Province's fourth batch of "Nine Treasures Eighteen Products" regional brand certification in October 2025.
• Pushen Pelvic Inflammation Capsules (蒲参盆腔炎胶囊 / Pu Shen) New drug currently in clinical trials representing the company's R&D investment in innovative traditional Chinese medicine formulations targeting pelvic inflammation treatment.

Quantifiable outcome

• Products received county-level intangible cultural heritage designation (October 2024)
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• 青岛农业大学 (Qingdao Agricultural University)coreStrategic or Co-development Partner · 27 April 2024三方签署合作协议，围绕生物医药领域开展深度合作。青岛农业大学周功克教授与半岛网页版-半岛(中国)官方总经理孙立宝为'药用银杏、刺五加深度开发研究基地'揭牌。合作聚焦科技成果落地转化，围绕鸡东县生物医药产业集群发展，共同打造'4321'现代化产业体系。
• 青岛云汉银杏科技发展有限公司 (Qingdao Yunhan Ginkgo Technology Development Co., Ltd.)minorStrategic or Co-development Partner · 27 April 2024与青岛云汉银杏科技发展有限公司、青岛农业大学三方签署合作协议，共同开展生物医疗领域深度合作交流，推进药用银杏和刺五加的深度开发研究。
• 西安天洋医药有限公司 (Xi'an Tianyang Pharmaceutical Co., Ltd.)minorStrategic or Co-development Partner · 1 October 20162016年10月与西安天洋医药有限公司达成战略合作，实现了合作互通、资源互补、平台互享，全面提升了企业经营实力、产品引进能力、企业抗风险能力。
• 国信医药科技（北京）有限公司 (Guoxin Medical Technology (Beijing) Co., Ltd.)coreStrategic or Co-development Partner · 1 January 20142014年携手国信医药科技（北京）有限公司合力打造未来医药产业链综合服务平台在北京成立。该平台以医药项目为纽带，汇聚国内极具成长性的研发企业、制药企业和经营企业，从产品选题立项到生产上市，充分发挥平台资源优势，打造医药'大产业链'。

Scale indicators4 records

Recent moves15 records

Expansion highlights6 records

Direct peers

• China Traditional Chinese Medicine Holdings: Sinopharm-affiliated TCM platform focused on branded Chinese medicine formulations and concentrated TCM granules. Comparable as a branded-TCM consolidator with GMP manufacturing and nationwide pharmaceutical distribution.
• Livzon Pharmaceutical Group: Diversified Chinese pharma group with a meaningful TCM/biologics portfolio and national sales coverage. Comparable for the mix of legacy TCM SKUs and modern clinical pipeline development within a single GMP-anchored platform.
• Pien Tze Huang (Zhangzhou Pien Tze Huang Pharmaceutical): Specialty Chinese pharma company with a heritage single-product franchise built on a classical formulation. Comparable for the strategy of monetizing a single classical-formula hero SKU within a GMP-certified, national-distribution company.
• Jilin Aodong Pharmaceutical: Northeast-China-based branded TCM and chemical-drug manufacturer with a similar regional-anchor model and national expansion ambitions. Highly comparable given shared Northeast China base, GMP-certified operations, and overlapping classical-formula repositioning strategy.

Broad incumbents

• Yunnan Baiyao Group: Diversified Chinese pharma/TCM leader with a strong branded portfolio, nationwide distribution, and growing health-products franchise. Comparable for branded-TCM positioning, national GTM, and category-defining single-product brands.
• Guangzhou Pharmaceutical (Baiyunshan): Large state-controlled Chinese pharma/TCM company with deep OTC and hospital channels across southern and national China. Comparable for branded TCM, GMP manufacturing, and southern-anchored national distribution model.
• China Resources Sanjiu Medical & Pharmaceutical: Large state-backed branded TCM and OTC pharma group (999) with a national sales network and broad CNS/respiratory SKUs. Comparable as a scaled Chinese branded-pharma competitor targeting overlapping hospital and retail channels.
• Beijing Tongrentang: Iconic traditional Chinese medicine manufacturer with centuries of heritage, GMP-certified facilities, and a deep national retail/hospital presence. Comparable as a heritage TCM brand built on classical formulas and GMP manufacturing.
• Shanghai Pharmaceuticals Holding: One of China's largest integrated pharma groups covering branded TCM, chemical drugs, and distribution. Comparable for the GMP manufacturing + national distribution + diversified branded pharma model.

Regional players

• Tianjin Tongrentang Group: Northern-China-branded TCM manufacturer leveraging the Tongrentang heritage outside Beijing. Comparable as a regionally anchored TCM manufacturer with national ambitions, sharing cold-climate classical-formula positioning.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/SegbayInc
• Facebookfacebook.com/958209274219252

Compliance14 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Segabay INC